Key Updates for Immuron Shareholders
Highlights:
- US Tariffs: Immuron does not expect significant impact from recent US tariffs on pharmaceuticals.
- Travelan Clinical Study: Topline results from this important clinical study are set for release in October 2025.
- IMM-529 Regulatory Milestone: The company plans to submit an Investigational New Drug application to the FDA for IMM-529 for Clostridioides difficile infections by mid-October 2025.
- ProIBS Commercial Launch: The Australian launch of ProIBS is anticipated for the fourth quarter of 2025.
- IMM-986 Pre-Clinical Progress: Initial pre-clinical research for IMM-986, targeting Vancomycin-resistant Enterococci, is expected to conclude by year-end 2025.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to share updates with shareholders regarding its progress on various fronts. As a biopharmaceutical company based in Australia, Immuron has been at the forefront of developing innovative therapies and expanding its market reach.
Sales Performance Overview
In a recent announcement, Immuron indicated that it achieved record sales leading up to the end of the financial year, which concluded on June 30. The company is on track to surpass sales figures from the first quarter of the previous fiscal year. The first-quarter results for FY25 will be reported in mid-October.
It's worth noting that Travelan, which is imported into the United States from Australia, functions as a dietary supplement, rather than a pharmaceutical product. This classification suggests that it won't be significantly affected by the aforementioned tariff announcements applied to pharmaceuticals.
Clinical Trial Developments
Immuron is currently developing three therapeutic products: IMM-124E (Travelan) for preventing traveler's diarrhea, IMM-529 for treating Clostridioides difficile infections, and IMM-986 aimed at combating Vancomycin-resistant Enterococci.
Research on IMM-124E
According to previous reports, the last patient visit for the Travelan field study is expected to take place in July 2025, with topline results anticipated in October 2025. Successful outcomes from this trial would enable Travelan to be included in traveler’s diarrhea guidelines, enhancing its market potential alongside strengthening relationships with the U.S. Department of Defense.
If results are favorable, Immuron plans to schedule an end-of-Phase-2 meeting with the FDA regarding IMM-124E, setting the stage for a Phase-3 clinical program.
Recent economic assessments indicate that the U.S. market for IMM-124E could reach approximately USD 102 million annually.
Progress on IMM-529
Immuron is actively working on submitting a new IND application to the FDA to begin clinical development for IMM-529 as a treatment option for Clostridioides difficile infections. The anticipated timeline for this submission is mid-October 2025, and success in this application is vital for progressing towards a Phase-2 clinical program.
In prior communications, market assessments suggested that peak revenues for IMM-529 in the United States could achieve around USD 400 million.
Launch Plans for ProIBS
Earlier announcements indicated that Immuron is on track for a limited launch of ProIBS in the fourth quarter of 2025, with a full launch in the first quarter of 2026. ProIBS has been designed as a medical product certified in Europe for alleviating symptoms associated with Irritable Bowel Syndrome.
The IBS treatment sector in Australia is a substantial part of the broader Digestives & Intestinal Remedies market, expected to generate around A$221 million in 2025 with an annual growth rate of 3.28%.
Pre-Clinical Trials for IMM-986
Immuron has partnered with Monash University to advance the development of a new treatment targeting Vancomycin-resistant Enterococci (VRE) under the name IMM-986. The emergence of antimicrobial resistance presents considerable challenges to global healthcare, leading to increased treatment costs and longer hospital stays.
VRE vaccines have shown promise in animal studies, and preliminary data suggests that IMM-986 is generating a positive antibody response. Further research is planned, with initial pre-clinical studies expected to begin by the end of 2025.
Thank you for your continued support.
Steven Lydeamore
Chief Executive Officer
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
Frequently Asked Questions
What are the key highlights shared by Immuron Limited?
Key highlights include updates on US tariffs, clinical study timelines, and regulatory milestones for their products.
What products are currently under development by Immuron?
Immuron is developing IMM-124E (Travelan), IMM-529, and IMM-986, targeting various infectious diseases.
When can shareholders expect the first quarter sales results for FY25?
First quarter sales results are set to be reported in mid-October.
What is the projected annual revenue for IMM-124E in the U.S.?
The yearly revenue for IMM-124E is projected to be approximately USD 102 million.
When is the launch planned for ProIBS?
A limited launch of ProIBS is expected in Q4 of 2025, with a full launch in Q1 of 2026.
